...Great. Good morning, and welcome back to the 42nd Annual Canaccord Genuity Global Growth Conference. I'm Kyle Rose. I'm one of the medical technology analysts here at Canaccord. Very glad to be back in person and see some faces rather than just Zoom screens. But I'm joined this morning by Dexcom. Dexcom is a leader and innovator in the design, development and commercialization of continuous glucose monitoring, which has really been one of the largest growth segments within med tech over the course of the last decade. So very pleased to be joined by the CFO, Jereme Sylvain; as well as the Head of Investor Relations, Sean Christensen. So we've got a fireside chat format here. I've got a list of questions I want to work through. I want to make it as interactive as possible. So raise your hand, and I'll do my best to weave anything in. And then just before we jump into questions here, just need to give the obligatory compliance disclosures that any disclosures if and where applicable, you can...
